Piramal Pharma Reports Quarterly Results: Standalone Profitability Contrasts Against Consolidated Performance
Piramal Pharma Limited announced its unaudited financial results for the quarter ended June 30, 2026. The Board of Directors approved these results during a meeting held on July 29, 2026.The company operates in a single segment. The Q1 results demonstrate distinct performance metrics when viewed at both the standalone and consolidated levels.
Key Financial Highlights (Q ended June 30, 2026)
| Metric | Standalone (Rs. in Crores) | Consolidated (Rs. in Crores) |
|---|---|---|
| Revenue from operations | 1,124.95 | 2,269.92 |
| Total Income | 1,239.58 | 2,359.33 |
| Profit before tax | 149.48 | (7.46) |
| Net Profit after tax | 113.48 | (69.39) |
| EPS (Basic) | 0.85 | (0.52) |
Operational and Financial Details
The standalone results indicated a total income of 1,239.58 Crores, with net profit after tax reported at 113.48 Crores. The earnings per equity share (EPS), based on the face value of Rs. 10 each, stood at 0.85 for the quarter.The consolidated results showed a revenue from operations of 2,269.92 Crores and total income of 2,359.33 Crores. However, the company reported a net profit after tax loss of (69.39) Crores at the consolidated level.
A review of the unaudited financial results provided details on key expenses and financial components for both segments:
| Particulars | Standalone (Q ended June 30, 2026) | Consolidated (Q ended June 30, 2026) |
|---|---|---|
| Cost of materials consumed | 649.70 Crores | 724.77 Crores |
| Employee benefits expense | 216.34 Crores | 675.63 Crores |
| Total Expenses | 1,090.10 Crores | 2,386.35 Crores |
The results from the previous financial year ended March 31, 2026, showed exceptional items aggregating to Rs. 92.51 crore for the standalone segment. This comprised an impairment of an intangible asset under development amounting to Rs. 65.57 crore and an incremental employee benefit cost assessed at Rs. 26.94 crore.
The unaudited consolidated results also reflect exceptional items from previous periods, aggregating to Rs. 196.14 crore for the year ended March 31, 2026. These included impairment of an intangible asset under development of Rs. 175.82 crore and incremental employee benefit cost at Rs. 26.94 crore.
PPLPHARMA Stock Price Movement
Today, Piramal Pharma Limited shares edged higher to close at ₹195.68, finishing with a 0.81% gain. The stock saw considerable activity during the session, with over 11.8 million shares traded.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.